{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:06Z","timestamp":1786112766544,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conventional image-guided radiotherapy (IGRT) typically relies on a computed tomography (CT)-based treatment planning process (planning CT, pCT) performed prior to the start of treatment. During this process, a patient-specific treatment plan is generated, which is then delivered to the patient with a linear accelerator on a daily basis, usually with image guidance to compensate for variations in patient setup. However, daily interfractional anatomical variations in target position, shape, and volume, as well as in surrounding organs at risk (OARs), can only be addressed indirectly by adding safety margins, resulting in larger irradiated volumes and potentially increased toxicity. Online adaptive radiotherapy (oART) is a promising and innovative technique to reduce such margins and, consequently, treatment-related toxicity. It uses daily imaging to generate a \u201cplan of the day\u201d that is aligned with the current patient anatomy, often supported by artificial intelligence (AI), while the patient remains on the treatment couch. Through daily image-guided re-optimization of the radiation treatment (RT) plan on the anatomy of the day, target coverage may also be improved. This approach is particularly attractive in the pelvic region, where high interfractional anatomical variability, for example due to peristalsis or changes in bladder and rectal filling, is frequently observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective registry-based cohort study will include patients with pelvic or thoracic tumors with an indication for RT treated with IGRT or oART using the Varian Ethos\u2122 system. The primary endpoint is defined as a 10% reduction in the rate of acute RT related toxicity (\u2265Common Terminology Criteria for Adverse Events (CTCAE) II\u00b0, v5.0) using oART. Secondary endpoints encompass clinical outcomes including late toxicities, tumor control rates, and patient-reported outcomes (PROs), as well as technical factors such as target volume, coverage, dose to OARs and anatomical variability score. While the cohort study compares IGRT versus oART for primary and secondary clinical endpoints, it also evaluates the real oART scenario against two hypothetical control scenarios for technical endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The introduction of oART promises a reduction in toxicities and improved target volume coverage, potentially resulting in enhanced tumor control rates. It is poised to be a pioneering technology in the field of radiation oncology. Given the absence of a direct comparison between IGRT and oART thus far, the prospective registry-based cohort study PRoART aims to address this gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinical trial number NCT06185062, Clinicaltrials.gov. Registered 12\/14\/2023. Last update 07\/29\/2026.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12880-026-02622-7","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:26:47Z","timestamp":1785943607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Online adaptive radiotherapy in pelvic and thoracic cancers - comparing toxicities, clinical outcomes and technical parameters between conventional image-guided radiotherapy and online adaptive radiotherapy \u2013 the study protocol for the prospective, registry-based cohort study (PRoART)"],"prefix":"10.1186","volume":"26","author":[{"given":"Laura Anna","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas Christian","family":"Scheele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Hendrik","family":"Droege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guhlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Tobias","family":"Oelmann-Avendano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bendrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Donath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Knaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Alexander","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Marie","family":"Zwerenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahalia Zoe","family":"Anczykowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Elisabeth","family":"Ammon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia Franziska","family":"Luise Bergau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta Friederike","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Anton","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Renata","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Frohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jona","family":"Bensberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Strau\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Asendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami Atejah","family":"El Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2622_CR1","unstructured":"Krebs RKI. Krebs in Deutschland f\u00fcr 2019\/2020. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/krebs_in_deutschland_node.html. 15 May 2024."},{"issue":"5","key":"2622_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clinicians. 2022;72(5):409\u201336. https:\/\/doi.org\/10.3322\/caac.21731.","journal-title":"CA Cancer J Clinicians"},{"issue":"8","key":"2622_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00066-024-02323-6","volume":"201","author":"J Fischer","year":"2025","unstructured":"Fischer J, Fischer LA, Bensberg J, Bojko N, Bouabdallaoui M, Frohn J, et al. CBCT-based online adaptive radiotherapy of the prostate bed: first clinical experience and comparison to nonadaptive conventional IGRT. Strahlenther Onkol. 2025;201(8):767\u201378. https:\/\/doi.org\/10.1007\/s00066-024-02323-6.","journal-title":"Strahlenther Onkol"},{"key":"2622_CR4","doi-asserted-by":"publisher","unstructured":"Byrne M, Archibald-Heeren B, Hu Y, Teh A, Beserminji R, Cai E, et al. Varian ethos online adaptive radiotherapy for prostate cancer: early results of contouring accuracy, treatment plan quality, and treatment time. J Appl Clin Med Phys. 2022;23(1):e13479. https:\/\/doi.org\/10.1002\/acm2.13479.","DOI":"10.1002\/acm2.13479"},{"issue":"5","key":"2622_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ijrobp.2013.07.041","volume":"87","author":"JM Michalski","year":"2013","unstructured":"Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the radiation therapy oncology group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys. 2013;87(5):932\u201338. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.07.041.","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"2622_CR6","doi-asserted-by":"publisher","unstructured":"Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One. 2016;11(5):e0154499. https:\/\/doi.org\/10.1371\/journal.pone.0154499.","DOI":"10.1371\/journal.pone.0154499"},{"key":"2622_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.radonc.2022.03.014","volume":"171","author":"LM \u00c5str\u00f6m","year":"2022","unstructured":"\u00c5str\u00f6m LM, Behrens CP, Calmels L, Sj\u00f6str\u00f6m D, Geertsen P, Mouritsen LS, et al. Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: initial experience and dosimetric benefits. Radiother Oncol. 2022;171:37\u201342. https:\/\/doi.org\/10.1016\/j.radonc.2022.03.014.","journal-title":"Radiother Oncol"},{"issue":"10","key":"2622_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3109\/0284186X.2014.928418","volume":"53","author":"J S\u00f8ndergaard","year":"2014","unstructured":"S\u00f8ndergaard J, Holmberg M, Jakobsen AR, Agerb\u00e6k M, Muren LP, H\u00f8yer M. A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta Oncologica. 2014;53(10):1321\u201328. https:\/\/doi.org\/10.3109\/0284186X.2014.928418.","journal-title":"Acta Oncologica"},{"issue":"33","key":"2622_CR9","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1200\/JCO.20.02530","volume":"39","author":"S Chopra","year":"2021","unstructured":"Chopra S, Gupta S, Kannan S, Dora T, Engineer R, Mangaj A, et al. Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer (PARCER): a randomized controlled trial. JCO. 2021;39(33):3682\u201392. https:\/\/doi.org\/10.1200\/JCO.20.02530.","journal-title":"JCO"},{"key":"2622_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.radonc.2022.01.039","volume":"168","author":"DS M\u00f8ller","year":"2022","unstructured":"M\u00f8ller DS, Lutz CM, Khalil AA, Alber M, Holt MI, Kandi M, et al. Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. Radiother Oncol. 2022;168:234\u201340. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.039.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2622_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","volume":"21","author":"U Nestle","year":"2020","unstructured":"Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, K\u00fcsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. The Lancet Oncol. 2020;21(4):581\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(20)30013-9.","journal-title":"The Lancet Oncol"},{"issue":"2","key":"2622_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","volume":"85","author":"DA Palma","year":"2013","unstructured":"Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;85(2):444\u201350. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.04.043.","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"4","key":"2622_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00066-016-0941-8","volume":"192","author":"M Flentje","year":"2016","unstructured":"Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT \u2013 Eine randomisierte Phase-III-Studie mit oralem Vinorelbin und Cisplatin plus konkomitanter Strahlentherapie gefolgt von konsolidierender Therapie mit oralem Vinorelbin und Cisplatin oder bestm\u00f6glicher supportiver Therapie bei nicht-kleinzelligem Lungenkarzinom Stadium III. Strahlenther Onkol. 2016;192(4):216\u201322. https:\/\/doi.org\/10.1007\/s00066-016-0941-8.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2622_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","volume":"35","author":"SG Chun","year":"2017","unstructured":"Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non\u2013small-Cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. JCO. 2017;35(1):56\u201362. https:\/\/doi.org\/10.1200\/JCO.2016.69.1378.","journal-title":"JCO"},{"key":"2622_CR15","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. 12 May 2024."},{"key":"2622_CR16","unstructured":"National Cancer Institute. Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/. 12 May 2024."},{"key":"2622_CR17","unstructured":"EORTC Quality of Life Group. Quality of life of cancer patients - EORTC - Quality of life: EORTC - Quality of life. https:\/\/qol.eortc.org\/questionnaire\/eortc-qlq-c30\/,https:\/\/qol.eortc.org\/questionnaire\/eortc-qlq-c30\/. 24 May 2023."},{"issue":"6","key":"2622_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/s0090-4295(00)00858-x","volume":"56","author":"JT Wei","year":"2000","unstructured":"Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899\u2013905. https:\/\/doi.org\/10.1016\/s0090-4295(00)00858-x.","journal-title":"Urology"},{"issue":"5","key":"2622_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","volume":"76","author":"KM Szymanski","year":"2010","unstructured":"Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76(5):1245\u201350. https:\/\/doi.org\/10.1016\/j.urology.2010.01.027.","journal-title":"Urology"},{"key":"2622_CR20","doi-asserted-by":"publisher","unstructured":"Thayaparan AJ, Mahdi E. The patient satisfaction questionnaire short form (PSQ-18) as an adaptable, reliable, and validated tool for use in various settings. Med Educ Online. 2013;18(1):10.3402\/meo.v18i0.21747. https:\/\/doi.org\/10.3402\/meo.v18i0.21747.","DOI":"10.3402\/meo.v18i0.21747"},{"issue":"2","key":"2622_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","volume":"12","author":"CM Nutting","year":"2011","unstructured":"Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. The Lancet Oncol. 2011;12(2):127\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(10)70290-4.","journal-title":"The Lancet Oncol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02622-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:42:47Z","timestamp":1785944567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02622-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2622"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02622-7","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval by the Ethics Committee of the Medical Faculty of the University Medical Center Goettingen was obtained (14\/9\/23 December 19, 2023). Prior to enrolling in the clinical study, each participant will provide written informed consent in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is not eligible regarding consent of publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"378"}}